ArticlePharmaceutics2024

First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration.

Wissam Aljundi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.